Stryker Adjusted EPS Rises 10.3% To $3.52, But CEO Says Quarter 'Did Fall Short Of Our Expectations'
The medical device maker's reported EPS fell 11.7% to $1.96 on a $293 million goodwill impairment, and it added $3.0 billion to its buyback.
Stryker's third-quarter sales rose 7.7% to $6.5 billion, yet Chair and CEO Kevin A. Lobo said the result "did fall short of our expectations." Reported earnings per share fell 11.7% to $1.96, while adjusted earnings per share rose 10.3% to $3.52, the company said in results released Thursday.
Two profit pictures
Reported net earnings fell 12.3% to $753 million. Reported operating margin was 15.9%, compared with 18.7% a year earlier. The quarter included a $293 million goodwill impairment, one of several items the company excludes from its adjusted figures. The others include acquisition costs, amortization of purchased intangibles, structural optimization and other special charges, and tax matters.
On the adjusted basis, net earnings rose 10.1% to $1.4 billion. Adjusted operating margin rose 60 basis points (0.60 percentage points) to 26.2%.
Lobo called the growth "good overall performance" in absolute terms. He added, "The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027."
Volume drives 7.7% organic growth
Stryker, which makes surgical equipment, implants, emergency care gear and the Mako robotic-arm technology, said organic sales growth matched the reported 7.7%, driven mainly by higher unit volume.
MedSurg and Neurotechnology sales rose 9.2% to $3.7 billion. Orthopaedics rose 5.7% to $2.9 billion, or 5.9% in constant currency.
Within those segments, endoscopy sales rose 13.9% to $1.02 billion. Ortho Tech climbed 15.8% to $754 million. Hips slipped 1.0% to $453 million, and knees rose 1.1% to $635 million.
Bigger buyback, narrower outlook
Stryker repurchased $1.0 billion of its stock in the quarter. Its board approved a $3.0 billion increase to the buyback program in October.
The company updated its 2026 guidance. It now expects organic sales growth of 6.5% to 7.0% and adjusted earnings per share of $14.80 to $14.90. The sales outlook includes a modestly positive pricing effect, and currency should be slightly favorable if rates hold near current levels.
Management holds its conference call at 4:30 p.m. ET Thursday to discuss the results and give an operational update.
For the first nine months, Stryker's adjusted earnings per share were $9.81, up from $9.16 a year earlier.
Sources
- 8-K Filing — STRYKER CORP (SYK) — SEC EDGAR
- Exhibit sykex991earningsq32026.htm — STRYKER CORP 8-K exhibit — SEC EDGAR
- Stryker reports third quarter 2026 operating results — globenewswire.com